Application of MDSCs in diagnosis and treatment of retinal neovascular diseases

By detecting and neutralizing MDSCs in patients with retinal neovascular diseases, using neutralizing antibodies to MDSCs for treatment, the shortcomings of existing treatment methods are solved, the diagnostic accuracy and treatment effect are improved, and retinal vascular lesions are significantly improved.

CN119001093AInactive Publication Date: 2024-11-22JIANGHAI STREET COMMUNITY HEALTH SERVICE CENT HAIZHU DISTRICT GUANGZHOU
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411087298.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-09
Publication Date
2024-11-22
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing treatment methods for retinal neovascular diseases are not ideal, especially the diagnosis and treatment of proliferating diabetic retinopathy and retinopathy in premature infants have problems such as many complications, repeated treatment, and insufficient benefits for some patients.

Method used

By detecting the content of myelogenic inhibitory cells (MDSCs), treatment was performed using neutralizing antibodies against MDSCs, reducing the avascular area and neovascular area and improving retinal vascular lesions.

Benefits of technology

MDSCs can be used as specific diagnostic markers and therapeutic targets for retinal neovascular diseases. Test kits and neutralizing antibodies can be used to improve diagnostic accuracy and therapeutic effect, significantly reduce the area of ​​neovascularization, and improve retinal vascular lesions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119001093A_ABST
    Figure CN119001093A_ABST
Patent Text Reader

Abstract

The invention provides application of MDSCs in diagnosis and treatment of retinal neovascular diseases. It is found that the content of MDSCs in peripheral blood of a patient with the retinal neovascular disease is remarkably increased, and a characteristic parameter ROC curve evaluation result shows that the MDSCs are high in diagnosis accuracy when used for diagnosing the retinal neovascular disease. In addition, treatment with a neutralizing antibody against MDSCs can reduce the area of a non-vascular region and the area of neovascularization and improve retinal vasculopathy. Therefore, the MDSCs can be used as a specific diagnostic marker and a therapeutic target of the retinal neovascular disease. The invention provides a novel convenient, rapid and non-invasive retina neovascular disease diagnosis method, and provides a novel target spot for treatment of retina neovascular diseases based on pathogenesis research.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to the application of MDSCs in the diagnosis and treatment of retinal neovascular diseases. Background Art

[0002] Retinal neovascularization (RNV) refers to the pathological formation of new blood vessels in the retinal tissue due to ischemia, hypoxia, etc. on the basis of the original blood vessels, which can cause secondary retinal hemorrhage, exudation, and even detachment, leading to blindness. Proliferative diabetic retinopathy (PDR) and retinopathy of prematurity (ROP) are both serious retinal neovascular diseases.

[0003] Myeloid Derived Suppressor Cells (MDSCs) are a group of immature heterogeneous myeloid-derived cells, composed of immature myeloid cells, monocytes-macrophages, dendritic cells and bone marrow precursor cells. They have been proven to be involved in the occurrence and development of various tumors, infectious diseases and autoimmune diseases.

[0004] As the prevalence of diabetes continues to increase worldwide, the prevalence of PDR continues to increase. However, the current clinical treatment of retinal neovascular diseases represented by PDR and ROP is not ideal. Commonly used methods include retinal laser photocoagulation, anti-vascular endothelial growth factor, etc., which have disadvantages such as many complications, repeated treatments, and only partial benefits for some patients. Therefore, the pathogenesis of RNV still needs to be explored in order to find new therapeutic targets for RNV. Summary of the invention

[0005] Based on this, the purpose of the present invention is to provide the application of MDSCs in the diagnosis and treatment of retinal neovascular diseases. The content of MDSCs is significantly increased in the peripheral blood of patients with retinal neovascular diseases, and the use of neutralizing antibodies against MDSCs can reduce the area of ​​avascular regions and neovascularization areas, and improve retinal vascular lesions.

[0006] To achieve the above objectives, the present invention adopts the following technical solutions.

[0007] The first aspect of the present invention provides the use of a reagent for detecting MDSCs in the preparation of a retinal neovascular disease detection kit.

[0008] In some embodiments, the phenotype of the MDSCs is HLA-DR - CD11b+ .

[0009] In some embodiments, the reagent is a flow cytometry detection reagent.

[0010] In some embodiments, the reagents include human anti-HLA-DR antibodies and human anti-CD11b antibodies labeled with different fluorescent groups.

[0011] In some embodiments, the sample tested is peripheral blood.

[0012] In some embodiments, the retinal neovascular disease is retinopathy of prematurity.

[0013] The second aspect of the present invention provides a method for in vitro screening of retinal neovascular disease detection reagents, comprising the following steps: using a candidate reagent to detect MDSCs; if the detection can be achieved, the candidate reagent can be used as a retinal neovascular disease detection reagent.

[0014] In some embodiments, the retinal neovascular disease is retinopathy of prematurity.

[0015] The third aspect of the present invention provides the use of MDSCs neutralizing antibodies in the preparation of drugs for treating human retinal neovascular diseases.

[0016] In some embodiments, the phenotype of the MDSCs is HLA-DR - CD11b + .

[0017] In some embodiments, the retinal neovascular disease includes retinopathy of prematurity and proliferative diabetic retinopathy.

[0018] The fourth aspect of the present invention provides the use of MDSCs neutralizing antibodies in the preparation of drugs for treating oxygen-induced retinopathy mice.

[0019] The present invention found that the content of MDSCs in the peripheral blood of patients with retinal neovascular disease was significantly increased, and the characteristic parameter ROC curve evaluation results showed that when MDSCs were used to diagnose retinal neovascular disease, AUC = 0.7637, and the diagnostic accuracy was high. Therefore, MDSCs can be used as a specific diagnostic marker for retinal neovascular disease, and the reagent for detecting MDSCs can be used to prepare a retinal neovascular disease detection kit.

[0020] Furthermore, treatment with neutralizing antibodies targeting MDSCs can reduce the area of ​​avascular regions and neovascularization areas, and improve retinal vascular lesions. Therefore, MDSCs can be used as a new therapeutic target for membranous neovascular diseases, and neutralizing antibodies targeting MDSCs can be used to prepare drugs for treating retinal neovascular diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 Flow cytometric diagrams show the proportion and statistical results of MDSCs in the peripheral blood of premature infants without ROP and premature infants with ROP.

[0022] Figure 2 This is the ROC curve analysis result.

[0023] Figure 3 This is the result of IB4 staining of retinal flat mount.

[0024] Figure 4 Figure 3 shows the proportion and statistical results of MDSCs in the blood and retina of OIR mice by flow cytometry.

[0025] Figure 5 The elimination of MDSCs results in a reduction in the area of ​​retinal vascular lesions. DETAILED DESCRIPTION

[0026] The experimental methods in the following examples of the present invention, where no specific conditions are specified, are usually carried out under conventional conditions or under conditions recommended by the manufacturers. The various commonly used chemical reagents used in the examples are all commercially available products.

[0027] Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as those commonly understood by those skilled in the art of the present invention. The terms used in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention.

[0028] The terms "including" and "having" and any variations thereof of the present invention are intended to cover non-exclusive inclusions. For example, a process, method, device, product or equipment comprising a series of steps is not limited to the listed steps or modules, but may optionally include steps not listed, or may optionally include other steps inherent to these processes, methods, products or equipment.

[0029] The “and / or” mentioned in the present invention describes the association relationship of associated objects, indicating that three relationships may exist. For example, A and / or B may represent three situations: A exists alone, A and B exist at the same time, and B exists alone.

[0030] The following describes the invention in conjunction with specific embodiments.

[0031] Example 1

[0032] This example studies the diagnostic value of MDSCs for retinal neovascular diseases.

[0033] 1 Experimental methods

[0034] 1.1 Research subjects

[0035] This study included 14 premature infants without ROP and 13 infants with ROP who were treated in Guangdong Provincial Women and Children's Health Care Hospital from May 2023 to January 2024. The diagnostic criteria were: "Chinese Expert Consensus on Classification and Treatment of Retinopathy of Prematurity (2023)". The premature infants were newborns with a gestational age of less than 37 weeks.

[0036] 1.2 Inclusion criteria

[0037] Premature infants who meet the diagnostic criteria guidelines were diagnosed through fundus screening.

[0038] 1.3 Exclusion criteria

[0039] Those with severe congenital defects, premature infants with developmental abnormalities; those with other eye lesions, such as intraocular masses, congenital cataracts, etc., who cannot complete the screening;

[0040] 1.4 Ethical Statement

[0041] The research content and methods involved in this study were in accordance with medical ethics standards and requirements, and the ethics number was 202301114. Informed consent was signed with the family members or guardians of the children.

[0042] 1.5 Flow cytometry of peripheral blood

[0043] (1) Blood collection: 1 mL of whole blood was collected from the ROP group and the non-ROP premature infant control group into a 5 mL EDTA anticoagulant tube. PBS buffer equal in volume to the blood sample was added and pipetted to mix and dilute. Be gentle to reduce damage to cells.

[0044] (2) Prepare separation fluid: Take 3 mL of human peripheral blood lymph separation fluid in a 15 mL centrifuge tube and prepare for the next step;

[0045] (3) Transfer centrifugation: Use a 1 mL pipette to slowly inject the diluted blood sample into the prepared 3 mL human peripheral blood lymph separation solution, and try to spread it on the separation solution. Set the centrifuge conditions: 18°C, 600 g, 5 for ascending, 1 for descending, and centrifuge for 30 min.

[0046] (4) Aspirate the white membrane: After the sample is centrifuged, take out the sample and observe that it is divided into four layers from top to bottom in the centrifuge tube: the first layer is the plasma layer, the second layer is the ring-shaped milky white mononuclear cell layer, the third layer is the transparent separation liquid layer, and the fourth layer is the red blood cell layer. Use a pipette to aspirate the middle white membrane layer, add an equal volume of PBS buffer for washing, centrifuge at 4°C, 500g, 5min, up 9, down 9; discard the supernatant;

[0047] (5) Red blood cell lysis: Take out the sample after centrifugation, discard the supernatant, add 5 mL of red blood cell lysis buffer, mix well by pipetting, and let stand at room temperature for 5 min;

[0048] (6) Stop red cell lysis: Add 3-5 times the volume of PBS to stop red cell lysis, make up to 15 mL of PBS buffer, and centrifuge at 4°C, 500g, for 5 min;

[0049] (7) Add 50uL of the prepared antibody mixture system (Percp / Cyanine5.5-CD11b and APC-cy7-HLA-DR) to each tube of sample, pipette and blow several times to allow the antibody and cell pellet to be fully mixed, then place the sample on ice or incubate in a 4° refrigerator for 25 minutes;

[0050] (8) Centrifugation: After the incubation time is over, add 1 mL of PBS buffer to each tube, centrifuge at 500 g for 5 min at 4 °C, and discard the supernatant;

[0051] (9) Sieving: Resuspend the cells in 250uL PBS buffer, then filter through a 70um nylon filter and transfer the sample to a 5mL flow cytometer (note that the sample should be labeled). Try to detect the sample using a flow cytometer within 1 hour.

[0052] (10) On-line: Turn on the Fortessa flow cytometer and check whether the instrument is in normal working condition. Then open the flow cytometry software, create a new folder, and name the files and test tubes according to the time and sample. Add a blank tube to adjust the basic voltage parameters of FSC and SSC so that the target cell population is in the appropriate position. Load the prepared samples in sequence, collect the appropriate number of cells for each sample, and finally export the collected samples to a folder. Export and download the data for later analysis.

[0053] 1.6 Statistical analysis methods

[0054] The experimental data analysis involved in this study was performed using GraphPad 8.0 statistical analysis software. The experimental data were displayed according to the principle of mean ± standard deviation (Mean ± SD). For the comparison between the two groups, if it was in accordance with the normal distribution, the two independent sample t test was selected, otherwise the Mann-Whitney test method was selected for inter-group comparison; the receiver operating characteristic (ROC) curve was constructed, and the area under the curve (AUC) was calculated to analyze the diagnostic value of immune cell MDSCs in predicting ROP disease. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, ns indicates no significant difference.

[0055] 2 Experimental results

[0056] 2.1 Calculation of the clinical sample size required for the ROP group and the control group

[0057] This study was tested to be in line with normal distribution, so two independent sample tests (with unequal variance) were used for the mean. The group without retinopathy of prematurity (non-ROP group) was the blank control, the group with retinopathy of prematurity (ROP group) was the experimental group, and the proportion of myeloid-derived suppressor cells in peripheral blood was the main outcome index. In this pilot experiment, the means and standard deviations of the two groups were (3.208, 1.034) and (6.754, 3.814), respectively, with α = 0.05 (bilateral) and β = 0.8. The sample size of the non-ROP group and the ROP group was calculated by PASS15 software as N1 = N2 = 12 cases (Table 1). The actual sample size was N1 = 14 cases and N2 = 13 cases, which met the statistical requirements.

[0058] Table 1

[0059]

[0060] 2.2 Clinical data of ROP group and control group

[0061] There were 14 controls without ROP in this study, with birth weight ranging from 0.92 to 2.60 kg (1.97±0.49) and corrected gestational age ranging from 34.57 to 38.29 weeks (36.18±1.15). There were 13 premature infants with ROP, with birth weight ranging from 0.83 to 1.74 kg (1.19±0.08) and corrected gestational age ranging from 34.71 to 45.71 weeks (37.07±0.79).

[0062] 3.3 Increased peripheral blood MDSCs in the ROP group

[0063] Blood samples from premature infants without ROP and premature infants with ROP were used to separate peripheral blood lymphocytes and stain for MDSCs (CD11b + HLA-DR - ), Figure 1 A is a gating strategy flow cytometric scatter plot of peripheral blood MDSCs between the non-ROP group and the ROP group. The data between the two groups were recorded on the flow cytometer and then statistically analyzed. The statistical results showed that there were differences in peripheral blood MDSCs between the two groups, and the ROP group was significantly higher than the non-ROP control group (P < 0.05, Figure 1 B).

[0064] Figure 1 The results of MDSCs detection in blood samples of premature infants without ROP and premature infants with ROP are shown in Figure 2. A: The difference between peripheral blood MDSCs (CD11b + HLA-DR + ) flow cytometry plot with gate strategy. B: Changes in the proportion of peripheral blood MDSCs between the two groups (n = 13-14 per group). The bar graph is expressed as mean ± standard deviation (Mean ± SD), and two independent sample t-tests were used, **P < 0.01.

[0065] 3.4 ROC curve evaluation

[0066] The ROC curve evaluation results of the characteristic parameters of the diagnostic value of MDSCs in peripheral blood are as follows Figure 2 As shown, AUC = 0.7637, sensitivity was 53.85%, specificity was 92.86%, P = 0.0198, the difference was statistically significant, suggesting the potential diagnostic value of MDSCs in diagnosing premature infants with or without ROP, as well as the important clinical significance of further exploring the related role of MDSCs cell populations in children with ROP.

[0067] Example 2

[0068] This example studies the therapeutic effect of MDSCs neutralizing antibodies on retinal neovascular diseases. The mouse oxygen-induced retinopathy (OIR) model was used for the study. OIR is an experimental animal model used to study retinal diseases and vascular abnormalities, and can be used to study the pathogenesis and treatment of ROP and PDR. The phenotype of MDSCs in mice is CD11b + Gr1 + .

[0069] 1 Experimental methods

[0070] 1.1 Experimental animals

[0071] C57BL / 6J pregnant mice were maintained at 25-30°C and 50% relative humidity with a 12-h light / dark cycle and provided with food and water. This experiment strictly complied with animal ethical standards.

[0072] 1.2 Establishment of the mouse oxygen-induced retinopathy (OIR) model

[0073] (1) Mouse husbandry: C57BL / 6 mice were housed in a barrier facility with free access to food and water and a 12-h light-dark cycle. They were allowed to mate freely and were regularly observed for pregnancy. Pregnant mice were housed individually in new cages after detection. The birth date of newborn mice was recorded, and the day of birth was designated as P0 (postnatal day 0).

[0074] (2) Modeling: The pups and lactating mothers on the seventh day after birth were transferred to an oxygen box with an oxygen content of 75±2% for 5 days. During this period, sufficient food and water resources were ensured so that the pups could obtain sufficient nutrition to meet their development needs. At P12, the pups and lactating mothers were taken out of the oxygen box, the state of continuous high-concentration oxygen inhalation was terminated, and they were returned to the indoor air environment for normal feeding. The modeling was completed after 5 days.

[0075] (3) Processing: Samples were collected at the corresponding age of mice according to experimental requirements, including days 12, 15, and 17 after birth. Mice were euthanized for subsequent experiments.

[0076] 1.3 Mouse retinal flow cytometry

[0077] (1) Retina separation: The control group and the mouse model group with oxygen-induced retinopathy were euthanized on day 17, and the eyeballs were removed and placed under a stereo microscope. The objective lens and eyepiece were adjusted so that the eyeballs could be fully observed, and the retinas were separated using ophthalmic scissors and forceps under the stereo microscope;

[0078] (2) Digestion of the retina: Place the retina in a prepared digestion solution (containing 2 mg / mL collagenase and DNase) diluted with PBS buffer and incubate in a 37°C water bath for 7–10 min. Tap the contents of the EP tube 1–2 times to allow full contact between the retina and the digestion solution. Stop when the solution becomes turbid and the retina is digested into small particles.

[0079] (3) Stop digestion: further blow the retinal tissue containing the digestion solution several times to make the retina further fully digested, filter through a 70 μm mesh, use a pipette to draw 1 mL of 2% newborn calf serum diluted with PBS buffer prepared in advance, and inject it into the mesh in mid-air, so that the cells on the filter are washed into the EP tube, and a retinal single cell suspension is fully obtained;

[0080] (4) Centrifugation: 500 g, 5 min, 4 degrees centrifugation, remove the supernatant to obtain the cell pellet;

[0081] (5) Configure the flow cytometry antibody system: According to the mouse MDSCs staining protocol (APC-Gr1, Super Bright TM 600-CD11b, eFluor TM 506-CD45) Calculate the total volume required for each antibody, specifically adjust the number of cells in each sample to no less than 2 million, stain each antibody with 0.5uL, and dilute the antibody with PBS buffer at a concentration of 1:100;

[0082] (6) Staining: Add 50uL of the prepared antibody mixture system to each tube of sample, pipette and blow several times to allow the antibody and cell pellet to be fully mixed, then place the sample on ice or incubate in a 4° refrigerator for 25min;

[0083] (7) Centrifugation: After the incubation time is over, add 1 mL of PBS buffer to each tube, centrifuge at 500 g for 5 min at 4 °C, and discard the supernatant;

[0084] (8) Sieving: Resuspend the cells in 250uL PBS buffer, then filter through a 70um nylon filter and transfer the sample to a 5mL flow cytometer (note that the sample should be labeled). Try to use the flow cytometer to detect the sample within 1 hour. Add 2uL of the dead-active dye antibody 7-AAD to each tube of sample within 15 minutes before the machine test.

[0085] (9) On-line: Turn on the Fortessa flow cytometer and check whether the instrument is in normal working condition. Then open the flow cytometry software, create a new folder, and name the files and test tubes according to the time and sample. Add a blank tube to adjust the basic voltage parameters of FSC and SSC so that the target cell population is in the appropriate position. Load the prepared samples in sequence, collect the appropriate number of cells for each sample, and finally export the collected samples to a folder. Export and download the data for later analysis.

[0086] 1.4 Preparation and staining of mouse blood single cell suspension

[0087] (1) Blood collection: P17 mice from the control group and the OIR model group were collected from the eye sockets of the mice. The blood was collected from the glass capillary tubes into 1.5 mL EP tubes containing EDTA. About 100 uL of blood was collected from each tube. The tubes were gently shaken to mix with the anticoagulant to reduce blood coagulation. The tubes were placed on ice and waited for the next step. The mice were then euthanized before the next step.

[0088] (2) Red blood cell lysis reaction: transfer the obtained blood sample to a 15 mL centrifuge tube, add 5 mL of red blood cell lysis buffer, mix well, lyse at room temperature for 8-10 min, terminate the red blood cell lysis reaction with 10 mL of PBS buffer, centrifuge at 500 g for 5 min at 4°C, and discard the supernatant;

[0089] (3) The preparation of flow cytometry antibodies, staining, centrifugation, screening and loading are the same as in step 1.3.

[0090] 1.5 Intraperitoneal injection of drugs

[0091] (1) Grouping: P7 mice of the same age were randomly divided into two groups and placed in an oxygen box for OIR modeling. The mice were marked with colored pens to distinguish between intraperitoneal injection of PBS (OIR-PBS group) or anti-mouse Ly6G / Ly6C (anti-Gr1) (OIR-anti-Gr1 group). Anti-Gr1 was used to eliminate MDSCs in the body.

[0092] (2) Drug grouping: The OIR-PBS group and the OIR-anti-Gr1 group were intraperitoneally injected with sterile buffer PBS or anti-Gr1 reagent (19.38ug / g) at P7, P12, and P15. The drugs were diluted to the appropriate concentration in advance to reduce operational errors caused by too high concentration and too small injection volume.

[0093] (3) Intraperitoneal injection: Before intraperitoneal injection, check whether the insulin needle is unobstructed and has good fluid tightness, and weigh the mouse to calculate the volume of solution required for injection. Gently grasp the mouse on its back in the palm of your hand, with the abdomen facing up and the head facing down. Disinfect the mouse's abdominal skin with 75% alcohol, then insert the needle at a 45-degree angle from one side of the abdomen until you feel a sense of emptiness. Continue the injection if there is no abnormal fluid after aspiration. Because mice are small and have a large abdominal cavity capacity, they are prone to leakage after injection. Therefore, pause for a few seconds after the injection and then slowly rotate the needle out to observe whether there is bleeding or leakage.

[0094] 1.6 IB4 staining of retinal flat mounts

[0095] (1) Fixation: After euthanizing the mice in each group, the eyeballs were removed and placed in a 1.5 mL Eppendorf tube (EP tube) filled with 4% paraformaldehyde for 2 h.

[0096] (2) Separation: Place the eyeball on a clean cell culture dish containing PBS buffer, and remove the cornea along the corneal limbus using ophthalmic scissors and forceps under a stereomicroscope, then remove the lens and carefully peel off the retina;

[0097] (3) Trimming: Use forceps to remove the remaining hyaloid blood vessels on the inner surface of the retina and cut the retina into a four-leaf clover shape, then transfer it to a 2 mL EP tube using a Pasteur pipette;

[0098] (4) Blocking: Place the retina in 50uL PBS-buffered saline solution containing 2% Triton X-100 and 5% goat serum and leave at room temperature for 2h;

[0099] (5) Preparation of IB4 solution: Take 3.675 mg CaCl2·2H2O (Thermo), dissolve it in 50 mL PBS; take 500 uL CaCl2·2H2O solution, add 500 ug IB4 powder reagent (1 ug / uL), mix thoroughly in dark place, store in separate containers at -20 degrees before use;

[0100] (6) Fluorescence staining: Use a pipette to remove the blocking solution, add 50uL of IB4 diluted to 0.02ug / uL (1:200), wrap the tube with aluminum foil to protect the sample from light, and incubate in a refrigerator at 4 degrees overnight;

[0101] (7) Washing: On the second day, wash the retina three times with 1 mL of PBS, 8 min each time, and place in a shaker in the dark with gentle shaking;

[0102] (8) Spreading: Use a Pasteur pipette to suck up the retina, then gently spread it on the slide, taking care to avoid damaging the retina. Keep the photosensitive surface facing down and use a fine-bristled brush to help spread the retina flat on the slide.

[0103] (9) Sealing: Cut a piece of sealing film of appropriate size with a hollow center to cover the retina and stick it around the arranged retina. Use absorbent paper to absorb excess water on the glass slide. Then drop an appropriate amount of aqueous sealing medium into the retina to seal the slide. Store at 4 degrees in the dark.

[0104] (10) Filming: The images were taken under a fully automatic in vivo imaging microscope. Finally, Photoshop 7.0 and ImageJ software were used to calculate and count the avascular area and neovascularization area of ​​the retina.

[0105] 1.7 Calculation of the area of ​​retinal neovascularization

[0106] (1) ImageJ software was used to analyze the superficial retinal vascular images taken by a fully automated in vivo imaging microscope (10x magnification);

[0107] (2) Select the Wand tool in the software, zoom in on the image appropriately to more clearly observe the neovascularization area, and then use the Wand tool to select the neovascularization areas one by one;

[0108] (3) Press the shortcut key to pop up the ROI interface, and add the selected neovascularization areas one by one and record them in ROImanage until the entire retinal neovascularization area is added;

[0109] (4) Click Measure in ROI manage to obtain the area size of all added neovascular regions, and then select Excel file to save;

[0110] (5) The sum of all neovascular areas obtained in the Excel file was calculated, and then the percentage of the sum of neovascular areas to the total retinal area was calculated.

[0111] 1.8 Calculation of retinal avascular area

[0112] (1) Photoshop 7.0 software was used to analyze the images of superficial retinal vessels taken by the fully automated in vivo imaging microscope (10x magnification);

[0113] (2) First, outline the outer edge of the entire vascularized retina and record the area of ​​the entire retinal area obtained in pixels;

[0114] (3) Then continue to outline the boundary of the ischemic area and record the size of the avascular area in the center of the retina in pixels;

[0115] (4) Calculate the percentage of the central avascular zone to the total retinal area.

[0116] 1.9 Statistical analysis methods

[0117] The experimental data analysis involved in this study was performed using GraphPad 8.0 statistical analysis software. The experimental data were displayed according to the principle of mean ± standard deviation (Mean ± SD). For the comparison between the two groups, if they were in accordance with the normal distribution, the two independent sample t test was used, otherwise the Mann-Whitney test method was used for inter-group comparison. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, ns indicates no significant difference.

[0118] 2 Experimental results

[0119] 2.1 Establishment of OIR model

[0120] The model was constructed according to conventional methods ( Figure 3 A), retinal flat mount IB4-stained specimen (red) observed under a fluorescence microscope, showing clear vascular branches. Figure 3 B and Figure 3As can be seen in Figure C, at P12 and P17, the retinal blood vessels of the control group mice projected from the optic disc along the periphery, and the surface was covered with a superficial vascular network, which was evenly distributed and well developed; while at P12, the retina of the OIR group mice formed a large avascular area in the center ( Figure 3 D), at P17, there is not only a large area of ​​blood vessels in the center of the retina, but also obvious expansion and bending of blood vessels in the peripheral area, and a large number of new blood vessel sprouts appear, some of which even merge into new blood vessel clusters, and the blood vessels are arranged in a disorderly manner ( Figure 3 E). Compared with the normal group, the most obvious changes in the retinas of the OIR group mice are the appearance of retinal avascular areas and increased neovascularization, which is consistent with the classic modeling results. Therefore, we have successfully constructed an OIR mouse model through this method, which can be used for subsequent research.

[0121] Figure 3 The results of IB4 staining of retinal flat mounts, where A: Schematic diagram of OIR modeling: P7 young mice were placed in 75% O2 for 5 days, and pathological changes of retinal vascular occlusion occurred; P12 to P17 were placed in 21% O2, and pathological changes of retinal neovascularization clusters occurred; BC: Results of IB4 staining of retinal blood vessels in the control group at P12 and P17; D: Results of IB4 staining of retinal blood vessels in the OIR model group at P12, the yellow area shows a large area without blood vessels; E: Results of IB4 staining of retinal blood vessels in the OIR model group at P17. The white box shows the vascular area and the enlarged image, and the white arrow shows part of the neovascular area. IB4: Isolectin B4.

[0122] 2.2 Increased MDSCs in the OIR model

[0123] Figure 4 The statistical results of MDSCs in the retina and blood. We used flow cytometry to detect the proportion of MDSCs in blood and retinal tissues. Both in the blood (P < 0.05, Figure 4 A) or retinal tissue (P < 0.0001, Figure 4 In B), MDSCs increased significantly in the OIR model, and the difference was statistically significant.

[0124] 2.3 Depletion of MDSCs improves retinal vascular disease

[0125] We then performed the next step to observe whether this group of MDSCs participates in the formation of retinal angiogenesis. We blocked MDSCs in the retina by intraperitoneal injection of PBS buffer or Gr-1 neutralizing antibody reagent into young mice, and observed the blood vessels in the retina by immunofluorescence ( Figure 5A), we observed that the avascular area in the OIR model in which the MDSCs cell population was neutralized by Gr-1 neutralizing antibody was significantly increased compared with that in the OIR model in which PBS was injected intraperitoneally (P < 0.05, Figure 5 B) and the area of ​​new blood vessels decreased significantly (P<0.05, Figure 5 C). This suggests that MDSCs are involved in the formation of retinal neovascularization in the OIR model, and retinal vascular lesions were significantly improved after depletion of MDSCs using neutralizing antibodies against MDSCs.

[0126] Figure 5 The results of the reduction of MDSCs in the area of ​​retinal vascular lesions, where: A: Immunofluorescence staining was used to evaluate the size of the retinal neovascularization area and the avascular area of ​​the OIR model mice intraperitoneally injected with PBS buffer or anti-Gr1 antibody at P7, P12 and P15. The yellow filled area represents the avascular area, and the yellow closed curve represents the neovascular area. B: Statistical analysis results of the avascular area of ​​the OIR-PBS group and the OIR-anti-Gr1 group; C: Statistical analysis results of the neovascular area of ​​the OIR-PBS group and the OIR-anti-Gr1 group. VO: avascular, avascular; NV: neovascular, neovascular; The bar graphs are expressed as mean ± standard deviation (Mean ± SD), all using the Mann-Whitney test, *P < 0.05, n = 8-10 per group, from two independent experiments.

[0127] In summary, MDSCs can serve as a new specific diagnostic marker and therapeutic target for retinal neovascular diseases.

[0128] The technical features of the above-described embodiments may be arbitrarily combined. To make the description concise, not all possible combinations of the technical features in the above embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0129] The above-mentioned embodiments only express several implementation methods of the present invention, and the description thereof is relatively specific and detailed, but it cannot be understood as limiting the scope of the patent of the present invention. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, which all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.

Claims

1. Application of reagents for detecting MDSCs in the preparation of retinal neovascular disease detection kits.

2. The use according to claim 1, characterized in that The phenotype of the MDSCs is HLA-DR - CD11b + .

3. The use according to claim 2, characterized in that The reagent is a flow cytometry detection reagent.

4. The use according to claim 3, characterized in that The reagents include human anti-HLA-DR antibodies and human anti-CD11b antibodies labeled with different fluorescent groups.

5. The use according to claim 1, characterized in that The sample for the test is peripheral blood.

6. The use according to any one of claims 1 to 5, characterized in that: The retinal neovascular disease is retinopathy of prematurity.

7. A method for in vitro screening of retinal neovascular disease detection reagents, characterized in that: The method comprises the following steps: using the candidate reagent to detect MDSCs; if the detection can be achieved, the candidate reagent can be used as a retinal neovascular disease detection reagent.

8. Application of MDSCs neutralizing antibodies in the preparation of drugs for treating human retinal neovascular diseases.

9. The use according to claim 8, characterized in that The phenotype of the MDSCs is HLA-DR - CD11b + and / or, The retinal neovascular diseases include retinopathy of prematurity and proliferative diabetic retinopathy.

10. Application of MDSCs neutralizing antibodies in the preparation of drugs for treating oxygen-induced retinopathy in mice.